Analysts predict that Novavax, Inc. (NASDAQ:NVAX) will report ($0.16) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Novavax’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Novavax reported earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The firm is expected to issue its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Novavax will report full-year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.52). For the next fiscal year, analysts expect that the firm will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.68) to ($0.38). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Novavax.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company’s revenue for the quarter was up 168.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) EPS.

Several equities research analysts recently weighed in on the company. Citigroup Inc. upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Tuesday. BidaskClub upgraded Novavax from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Zacks Investment Research upgraded Novavax from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, August 16th. Seaport Global Securities restated a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $1.50 price target on shares of Novavax in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.92.

In other Novavax news, Director James F. Young sold 175,000 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.00% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in NVAX. Chicago Equity Partners LLC bought a new stake in Novavax in the second quarter worth $1,852,000. JPMorgan Chase & Co. boosted its holdings in Novavax by 40.1% in the second quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company’s stock worth $5,976,000 after acquiring an additional 1,488,403 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Novavax by 4.5% in the first quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after acquiring an additional 938,581 shares in the last quarter. Nationwide Fund Advisors boosted its holdings in Novavax by 555.1% in the second quarter. Nationwide Fund Advisors now owns 1,024,020 shares of the biopharmaceutical company’s stock worth $1,178,000 after acquiring an additional 867,700 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Novavax by 38.7% in the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock worth $1,944,000 after acquiring an additional 471,347 shares in the last quarter. 44.81% of the stock is currently owned by institutional investors and hedge funds.

Novavax (NVAX) traded up 6.86% during trading on Tuesday, hitting $1.09. The company’s stock had a trading volume of 7,061,997 shares. The firm has a 50 day moving average of $1.12 and a 200 day moving average of $1.06. The firm’s market cap is $315.99 million. Novavax has a 12 month low of $0.73 and a 12 month high of $1.78.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/31/0-16-earnings-per-share-expected-for-novavax-inc-nvax-this-quarter.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.